Loading...
Please wait, while we are loading the content...
Similar Documents
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
| Content Provider | Semantic Scholar |
|---|---|
| Author | Jr. Charles F. Shaefer |
| Copyright Year | 2016 |
| Abstract | In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes. |
| Starting Page | 81 |
| Ending Page | 85 |
| Page Count | 5 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/ba/81.PMC4833487.pdf |
| PubMed reference number | 27092017 |
| Alternate Webpage(s) | https://doi.org/10.2337/diaclin.34.2.81 |
| DOI | 10.2337/diaclin.34.2.81 |
| Journal | Clinical diabetes : a publication of the American Diabetes Association |
| Volume Number | 34 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | A1C Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent GCG gene Glucagon Glucagon-Like Peptide 1 Glucagon-Like Peptide Receptors Glucagon-Like Peptides Hypoglycemia Incretins Lixisenatide Peptide PHI Therapeutic procedure receptor |
| Content Type | Text |
| Resource Type | Article |
